Sponsor

University Hospital, Gentofte, Copenhagen

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name University Hospital, Gentofte, Copenhagen appears in 98 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials98
Recruiting shown2
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

60 shown
Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy HumansNCT07506369 · lead sponsor · 2026-04-01
RECRUITING
The Role of Oxytocin in Regulating Blood GlucoseNCT06334172 · lead sponsor · 2024-01-01
RECRUITING
Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide TreatmentNCT07171723 · lead sponsor · 2025-09-01
COMPLETED
Effects of Antagonizing the Ghrelin Receptor on Brain Food Cue Reactivity in ObesityNCT06845033 · lead sponsor · 2025-05-01
ACTIVE_NOT_RECRUITING
Understanding How Gut and Brain Barriers Are Linked to Inflammation in ObesityNCT06787001 · lead sponsor · 2025-04-01
COMPLETED
The Effect of Oxytocin on the Alpha Cell Response to Hypoglycaemia in Patients With Type 1 DiabetesNCT06881459 · lead sponsor · 2025-03-25
COMPLETED
Investigating Glucose Metabolism of LEAP2 With Total-body PET/CTNCT06254365 · lead sponsor · 2024-02-21
ACTIVE_NOT_RECRUITING
The Role of Oxytocin-receptor Signalling in Physiological Regulation of Eating Behaviour in Individuals with ObesityNCT06189001 · lead sponsor · 2024-01-01
COMPLETED
Dapiglutide for the Treatment of ObesityNCT05788601 · lead sponsor · 2023-04-27
ACTIVE_NOT_RECRUITING
Neuronostatin - a Glucagonotropic Agent in Humans?NCT06143267 · lead sponsor · 2022-12-06
COMPLETED
LEAP2 on Postprandial Glucose Metabolism and Food Intake n Obese MalesNCT05603598 · lead sponsor · 2022-08-24
UNKNOWN
The Effect of Glucose-dependent Insulinotropic Polypeptide on the Alpha Cell Response to Hypoglycaemia in Patients with Type 1 DiabetesNCT06137586 · lead sponsor · 2022-08-10
COMPLETED
LEAP2 Kinetics in Healthy IndividualsNCT04897984 · lead sponsor · 2021-05-24
COMPLETED
The Relationship Between Inflammatory ARTritis and CArdiac DIseAseNCT05647577 · lead sponsor · 2021-01-01
ACTIVE_NOT_RECRUITING
LEAP2 on Postprandial Glucose Metabolism and Food IntakeNCT04621409 · lead sponsor · 2020-11-17
COMPLETED
The Insulin Response to the Gut Hormone GIP After Near-normalisation of Plasma Glucose in Patients With Type 2 DiabetesNCT04228484 · lead sponsor · 2020-01-07
COMPLETED
The Effect of Curcumin on the Development of Prednisolone-induced Hepatic Insulin ResistanceNCT04315350 · lead sponsor · 2019-12-01
TERMINATED
The Role of Pregnancy-induced Gallbladder Dysmotility in the Pathophysiology of Gestational Diabetes MellitusNCT04108065 · lead sponsor · 2019-10-02
COMPLETED
Bariatric Surgery on NASHNCT04043585 · lead sponsor · 2019-07-31
COMPLETED
GA 6: The Blood Glucose-lowering Effect of Glucose-dependent Insulinotropic PolypeptideNCT03845179 · lead sponsor · 2019-05-29
COMPLETED
Involvement of Dipeptidyl Peptidase-4 and Sodium-glucose Co-transporter-2 in Extrapancreatic Glucagon SecretionNCT04061473 · lead sponsor · 2019-04-02
COMPLETED
Mind-Body Approaches for Medical ConditionsNCT03888261 · lead sponsor · 2019-04-01
UNKNOWN
Liver-enriched Antimicrobial Peptide 2NCT04043065 · lead sponsor · 2019-01-28
COMPLETED
GIP/GLP-1 Co-Activity in Subjects With Overweight and Type 2 Diabetes: Lowering of Food IntakeNCT03526289 · lead sponsor · 2017-11-08
COMPLETED
Delineation of the Role of Glucagon-like Peptide-1 Signalling in Relation to Increased Carbohydrate Content in the Distal Small IntestinesNCT03241303 · lead sponsor · 2017-08-01
COMPLETED
Effect of GIP After a Meal in Patients With Type 2 DiabetesNCT03702660 · lead sponsor · 2017-08-01
COMPLETED
The Effect of Insulin-induced Hypoglycaemia on Gut-derived Glucagon Secretion (Px-Hypo)NCT04064203 · lead sponsor · 2017-07-05
COMPLETED
The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without SulphonylureaNCT03081676 · lead sponsor · 2017-03-08
COMPLETED
Investigation of Acute Physiological Effects of Aspiration TherapyNCT03389269 · lead sponsor · 2017-03-01
COMPLETED
Hypoglycaemia and Cardiac Arrhythmias in Type 2 DiabetesNCT03150030 · lead sponsor · 2017-02-01
COMPLETED
The Effect of HMG-CoA Reductase Inhibition on Postprandial GLP-1 SecretionNCT03018444 · lead sponsor · 2016-10-01
COMPLETED
The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 InhibitorsNCT02792400 · lead sponsor · 2016-05-01
COMPLETED
Delineation of the Diabetogenic Role of Extrapancreatic Glucagon in Totally Pancreatectomised Patients Using Glucagon Receptor AntagonismNCT02944110 · lead sponsor · 2016-04-01
UNKNOWN
Insulin Sensitivity in Patients With Atopic DermatitisNCT03003793 · lead sponsor · 2015-11-01
COMPLETED
Dissection of the Gastrointestinal-mediated Glucose Disposal and Incretin Defect in Patients With Type 2 DiabetesNCT02669524 · lead sponsor · 2015-10-01
COMPLETED
GIP/GLP-1 Co-Activity in Subjects With Obesity: Lowering of Food IntakeNCT02598791 · lead sponsor · 2015-10-01
COMPLETED
The Impact of Lixisenatide on Postprandial Glucose Tolerance in Pancreatectomised SubjectsNCT02640118 · lead sponsor · 2015-08-01
COMPLETED
Shared Care for Patients With Type 2 Diabetes Across the Primary and Secondary Health Care SectorNCT02586545 · lead sponsor · 2015-08-01
COMPLETED
Effect of Metformin and Cholecystokinin-mediated Gallbladder Emptying on GLP-1 Secretion in Type 2 DiabetesNCT02497313 · lead sponsor · 2015-07-01
COMPLETED
Hyperglucagonaemia in Patients With Type 2 Diabetes - Role of Glucagon ClearanceNCT02475421 · lead sponsor · 2015-05-01
COMPLETED
Effect of Smoking on Postprandial Gastric Emptying, Glucose Tolerance and Secretion of Gut and Pancreatic HormonesNCT02497651 · lead sponsor · 2015-05-01
COMPLETED
Effect of Bile Acid Secretion and Sequestration on GLP-1 SecretionNCT02445508 · lead sponsor · 2015-05-01
COMPLETED
Outpatient Follow-up on Demand in Rheumatoid ArthritisNCT04476875 · lead sponsor · 2015-02-01
COMPLETED
Effect of Bile Acid Sequestration on Postprandial GLP-1 Secretion, Glucose Homeostasis and Gut MicrobiotaNCT02061124 · lead sponsor · 2014-02-01
COMPLETED
The Role of Metformin and Colesevelam in Human GLP-1 SecretionNCT02050074 · lead sponsor · 2014-01-01
COMPLETED
Life Without DiabetesNCT02212665 · lead sponsor · 2014-01-01
COMPLETED
Endogenous Glucoseproduction in Patients With Type 2 Diabetes Mellitus During Oral Glucose and iv. Glucose InfusionNCT02010827 · lead sponsor · 2013-11-01
COMPLETED
COPD-EXA-REHAB. Early Pulmonary Rehabilitation of Patients With Acute Exacerbation of COPDNCT02987439 · lead sponsor · 2013-11-01
COMPLETED
Involvement of Extrapancreatic Factors on Gastrointestinal-mediated Glucose DisposalNCT02006459 · lead sponsor · 2013-09-01
COMPLETED
Home Non Invasive Ventilation (NIV) Treatment for COPD-patients After a NIV-treated ExacerbationNCT01513655 · lead sponsor · 2013-07-01
UNKNOWN
Correlation Between Plasma- and Endothelial DPP-4 ActivityNCT02192853 · lead sponsor · 2013-05-01
COMPLETED
Effect of Bile Acids on GLP-1 SecretionNCT01666223 · lead sponsor · 2012-11-01
COMPLETED
Severe Heart Failure and Homebased Rehabilitation - An Intersectoral Randomized Controlled TrialNCT01669395 · lead sponsor · 2012-09-01
UNKNOWN
The Effects of GLP-1 in Maturity-Onset Diabetes of The Young (MODY)NCT01610934 · lead sponsor · 2012-08-01
COMPLETED
Eradication of Gut MicrobiotaNCT01633762 · lead sponsor · 2012-04-01
COMPLETED
Vasodilatory and Metabolic Effects of Glucagon-like Peptide-1 in Periphery Circulation in Patients With and Without Type 2 Diabetes MellitusNCT01689051 · lead sponsor · 2012-03-01
COMPLETED
The Effect of GLP-1 on the Inhibition of Glucagon SecretionNCT01507597 · lead sponsor · 2011-12-01
COMPLETED
Pathophysiological Implications of the Incretin Hormones in Patients With Liver Disease With and Without DiabetesNCT01492283 · lead sponsor · 2011-12-01
COMPLETED
Importance of Meal Fat Content and Gall Bladder Emptying for Postprandial GLP-1 Secretion in Type 2 Diabetes PatientsNCT01374594 · lead sponsor · 2011-06-01
COMPLETED
Anatomical and Physiological Characterisation of the Gut Endocrine Cells in Healthy and in Patients With Type 2 DiabetesNCT03044860 · lead sponsor · 2011-03-01
COMPLETED

Drugs studied in this sponsor's trials

26 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing University Hospital, Gentofte, Copenhagen as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
placebo7
metformin3
oxytocin3
cholecystokinin2
colesevelam2
empagliflozin2
insulin aspart, human2
liraglutide2
placebo RxCUI 8375 · Lead sponsor in 5 linked trial(s) · 0 currently recruiting 7 trials metformin RxCUI 6809 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 3 trials oxytocin RxCUI 7824 · Lead sponsor in 3 linked trial(s) · 1 currently recruiting 3 trials cholecystokinin RxCUI 2420 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials colesevelam RxCUI 141626 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials empagliflozin RxCUI 1545653 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 2 trials insulin aspart, human RxCUI 51428 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 2 trials liraglutide RxCUI 475968 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 2 trials placebo Oral Tablet RxCUI 375221 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials acarbose RxCUI 16681 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial adalimumab RxCUI 327361 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial adenosine RxCUI 296 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial atorvastatin RxCUI 83367 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial chenodeoxycholic acid RxCUI 2323 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial dexamethasone RxCUI 3264 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial empagliflozin 25 MG RxCUI 1545665 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial glimepiride RxCUI 25789 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial infliximab RxCUI 191831 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial insulin detemir RxCUI 139825 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial Januvia RxCUI 638596 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial linagliptin RxCUI 1100699 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial lixisenatide RxCUI 1440051 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial prednisolone RxCUI 8638 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial sevelamer RxCUI 214824 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor81
collaborator17
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.